Skip to main content
. 2012 Jun 6;4(8):705–718. doi: 10.1002/emmm.201101105

Figure 5. p53 mutation, LOH and apoptosis in tumours from p53 +/− mice with bi-allelic Igf2 expression (H19 −m/+p).

Figure 5

  1. Proportion of p53+/− tumours with LOH/mutation was significantly reduced in tumours from mice bi-allelic for Igf2 (H19−m/+p), compared to mice null for Igf2+m/−p and WT (**p < 0.002, Fisher's exact test).
  2. 100% of sarcomas and carcinomas from H19−m/+p, p53+/− retain an intact WT p53 allele (n = 9), compared to 100% of LOH in the littermate p53+/− control mice (n = 5; **p = 0.0005, Fisher's exact test)
  3. Sarcomas with intact WT p53 (n = 6) had significantly higher Igf2 mRNA expression than lymphomas and carcinomas, irrespective of p53 allelic status (p < *0.05–***0.01, one-way ANOVA, Tukey's multiple comparison). Sample annotation is as for genotypes in Fig 4A and B.
  4. Solid tumours (n = 8) from H19−m/+p, p53+/− mice had significantly fewer apoptotic cells, assessed by staining for cleaved caspase-3 (right) than solid tumours from H19+m/+p, p53+/− mice (n = 4, *p = < 0.05, **p = < 0.01, ***p < 0.001, one-way ANOVA, Tukey's multiple comparison). Blue, male; Red, female.